ALJA STEL ET AL: "The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3.", THE JOURNAL OF IMMUNOLOGY, vol. 173, no. 10, 1 November 2004 (2004-11-01), pages 6009-6016, XP055089413, ISSN: 0022-1767 (B1)

XIONG D ET AL: "Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 X anti-CD3 bispecific diabody", CANCER LETTERS, NEW YORK, NY, US, vol. 177, 1 January 2002 (2002-01-01), pages 29-39, XP002980486, ISSN: 0304-3835, DOI: 10.1016/S0304-3835(01)00758-3 (B1)

CARTER P J: "POTENT ANTIBODY THERAPEUTICS BY DESIGN", THE JOURNAL OF IMMUNOLOGY, NATURE PUB. GROUP, vol. 6, 7 April 2006 (2006-04-07), pages 343-357, XP007901440, ISSN: 1474-1733, DOI: 10.1038/NRI1837 (B1)

EP-A2- 2 500 353 (B1)

GALL J M ET AL: "T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20<+> malignant B cells and bypass complement-mediated rituximab resistance in vitro", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC, US, vol. 33, no. 4, 1 April 2005 (2005-04-01), pages 452-459, XP027605406, ISSN: 0301-472X [retrieved on 2005-04-01] (B1)

LIU F ET AL: "Improvement in soluble expression levels of a diabody by exchanging expression vectors", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, vol. 62, no. 1, 1 November 2008 (2008-11-01), pages 15-20, XP025473717, ISSN: 1046-5928, DOI: 10.1016/J.PEP.2008.07.002 [retrieved on 2008-07-18] (B1)

MICHAEL STANGLMAIER ET AL: "Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels", INTERNATIONAL JOURNAL OF CANCER, vol. 123, no. 5, 1 September 2008 (2008-09-01), pages 1181-1189, XP055089407, ISSN: 0020-7136, DOI: 10.1002/ijc.23626 (B1)

PAVEL STROP ET AL: "Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 420, no. 3, 17 April 2012 (2012-04-17), pages 204-219, XP028521423, ISSN: 0022-2836, DOI: 10.1016/J.JMB.2012.04.020 [retrieved on 2012-04-25] (B1)

US-A1- 2007 081 993 (B1)

US-A1- 2010 331 527 (B1)

WARK K L ET AL: "Latest technologies for the enhancement of antibody affinity", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, vol. 58, no. 5-6, 7 August 2006 (2006-08-07), pages 657-670, XP024892147, ISSN: 0169-409X, DOI: 10.1016/J.ADDR.2006.01.025 [retrieved on 2006-08-07] (B1)

WO-A1-2004/106383 (B1)

WO-A1-2005/040220 (B1)

WO-A1-2007/093630 (B1)

WO-A1-2009/018411 (B1)

WO-A1-2011/090762 (B1)

WO-A2-2004/106380 (B1)

WO-A2-2007/024715 (B1)

WO-A2-2007/042261 (B1)

WO-A2-2008/119567 (B1)

ARCHANA THAKUR ET AL: "Activated T cells from umbilical cord blood armed with anti-CD3 x anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants", TRANSFUSION, vol. 52, no. 1, 11 July 2011 (2011-07-11), pages 63-75, XP055034409, ISSN: 0041-1132, DOI: 10.1111/j.1537-2995.2011.03232.x (B1)